1 |
MTOR
| [16] Phospholipase D signaling pathway Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Neutrophil extracellular trap formation, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Pathways in cancer, Proteoglycans in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00753
D00753
|
Sirolimus
| [41] 2 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
2 |
MTOR
| [16] Phospholipase D signaling pathway Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Neutrophil extracellular trap formation, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Pathways in cancer, Proteoglycans in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D02714
D02714
|
Everolimus
| [9] 34 34, 67, 89, 96, 137, 157, 158, 228, 277 |
3 |
MTOR
| [16] Phospholipase D signaling pathway Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Neutrophil extracellular trap formation, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Pathways in cancer, Proteoglycans in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D06068
D06068
|
Temsirolimus
| [4] 13 13, 34, 89, 331 |
4 |
IGF1R
| [12] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Ovarian steroidogenesis, Progesterone-mediated oocyte maturation, Pathways in cancer, Transcriptional misregulation in cancer, Proteoglycans in cancer, Prostate cancer | D03297
D03297
|
Mecasermin
| [6] 65 65, 78, 96, 168, 265, 299 |
5 |
IGF1R
| [12] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Ovarian steroidogenesis, Progesterone-mediated oocyte maturation, Pathways in cancer, Transcriptional misregulation in cancer, Proteoglycans in cancer, Prostate cancer | D04870
D04870
|
Mecasermin
| [6] 65 65, 78, 96, 168, 265, 299 |
6 |
IGF1R
| [12] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Ovarian steroidogenesis, Progesterone-mediated oocyte maturation, Pathways in cancer, Transcriptional misregulation in cancer, Proteoglycans in cancer, Prostate cancer | D09680
D09680
|
Teprotumumab
| [1] 51 51 |
7 |
IGF1R
| [12] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Ovarian steroidogenesis, Progesterone-mediated oocyte maturation, Pathways in cancer, Transcriptional misregulation in cancer, Proteoglycans in cancer, Prostate cancer | D09925
D09925
|
Linsitinib
| [1] 232 232 |
8 |
INSR
| [9] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Non-alcoholic fatty liver disease | D00085
D00085
|
Insulin human
| [2] 96 96, 156 |
9 |
INSR
| [9] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Non-alcoholic fatty liver disease | D03230
D03230
|
Insulin human
| [2] 96 96, 156 |
10 |
INSR
| [9] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Non-alcoholic fatty liver disease | D03250
D03250
|
Insulin glargine
| [1] 299 299 |
11 |
INSR
| [9] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Non-alcoholic fatty liver disease | D04539
D04539
|
Insulin detemir
| [1] 299 299 |
12 |
PIK3CA
| [40] Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11158
D11158
|
Leniolisib
| [2] 53 53, 65 |
13 |
PIK3CB
| [40] Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11158
D11158
|
Leniolisib
| [2] 53 53, 65 |
14 |
PIK3CD
| [40] Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11158
D11158
|
Leniolisib
| [2] 53 53, 65 |
15 |
PIK3CD
| [40] Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11437
D11437
|
Parsaclisib
| [3] 35 35, 53, 61 |
16 |
PRKAA1
| [6] mTOR signaling pathway mTOR signaling pathway, PI3K-Akt signaling pathway, Tight junction, Thermogenesis, Oxytocin signaling pathway, Non-alcoholic fatty liver disease | D00944
D00944
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
17 |
PRKAA1
| [6] mTOR signaling pathway mTOR signaling pathway, PI3K-Akt signaling pathway, Tight junction, Thermogenesis, Oxytocin signaling pathway, Non-alcoholic fatty liver disease | D04966
D04966
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
18 |
PRKAA2
| [6] mTOR signaling pathway mTOR signaling pathway, PI3K-Akt signaling pathway, Tight junction, Thermogenesis, Oxytocin signaling pathway, Non-alcoholic fatty liver disease | D00944
D00944
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
19 |
PRKAA2
| [6] mTOR signaling pathway mTOR signaling pathway, PI3K-Akt signaling pathway, Tight junction, Thermogenesis, Oxytocin signaling pathway, Non-alcoholic fatty liver disease | D04966
D04966
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
20 |
MAP2K1
| [36] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09666
D09666
|
Selumetinib
| [1] 34 34 |
21 |
MAP2K1
| [36] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10175
D10175
|
Trametinib
| [4] 2 2, 34, 279, 280 |
22 |
MAP2K1
| [36] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10405
D10405
|
Cobimetinib
| [1] 280 280 |
23 |
MAP2K1
| [36] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10604
D10604
|
Binimetinib
| [1] 34 34 |
24 |
MAP2K2
| [29] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09666
D09666
|
Selumetinib
| [1] 34 34 |
25 |
MAP2K2
| [29] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10175
D10175
|
Trametinib
| [4] 2 2, 34, 279, 280 |
26 |
MAP2K2
| [29] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10405
D10405
|
Cobimetinib
| [1] 280 280 |
27 |
MAP2K2
| [29] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10604
D10604
|
Binimetinib
| [1] 34 34 |
28 |
RAF1
| [31] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D06272
D06272
|
Sorafenib
| [2] 34 34, 86 |
29 |
RAF1
| [31] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08524
D08524
|
Sorafenib
| [2] 34 34, 86 |
30 |
BRAF
| [17] Rap1 signaling pathway Rap1 signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer | D06272
D06272
|
Sorafenib
| [2] 34 34, 86 |
31 |
BRAF
| [17] Rap1 signaling pathway Rap1 signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer | D08524
D08524
|
Sorafenib
| [2] 34 34, 86 |
32 |
BRAF
| [17] Rap1 signaling pathway Rap1 signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer | D10064
D10064
|
Dabrafenib
| [1] 34 34 |
33 |
TNF
| [28] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D00742
D00742
|
Etanercept
| [17] 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298 |
34 |
TNF
| [28] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D00754
D00754
|
Thalidomide
| [20] 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
35 |
TNF
| [28] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
36 |
TNF
| [28] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D02597
D02597
|
Adalimumab
| [18] 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 |
37 |
TNF
| [28] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D02598
D02598
|
Infliximab
| [27] 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
38 |
TNF
| [28] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D03441
D03441
|
Certolizumab pegol
| [8] 37 37, 46, 49, 96, 97, 107, 226, 271 |
39 |
TNF
| [28] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D04358
D04358
|
Golimumab
| [8] 46 46, 56, 84, 96, 97, 107, 270, 271 |
40 |
TNF
| [28] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D04687
D04687
|
Lenalidomide
| [8] 16 16, 26, 28, 34, 49, 284, 300, 331 |
41 |
TNF
| [28] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D05393
D05393
|
Pegsunercept
| [1] 46 46 |
42 |
TNF
| [28] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D08976
D08976
|
Pomalidomide
| [6] 28 28, 34, 51, 85, 227, 331 |
43 |
TNF
| [28] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D09944
D09944
|
Ozoralizumab
| [1] 46 46 |